



ABFERO EXPANDS MANAGEMENT TEAM WITH APPOINTMENT OF JEFF HARDER AS VICE PRESIDENT FOR ADMINISTRATION AND GENERAL COUNSEL

Boston, MA, [August 28, 2020] – AbFero, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the appointment of Jeff Harder as Vice President for Administration and General Counsel. Mr. Harder, who as a Texas-based attorney has more than 30 years' experience working with venture capitalists, technology and life science companies, and entrepreneurs, brings a deep expertise in public and private financings, corporate compliance, and overall business matters to AbFero.

"We welcome Jeff, who is coming aboard as we're rapidly approaching an inflection point," said Thomas X. Neenan, CEO of AbFero. "Until recently, the role of iron as a therapeutic target has been underappreciated, but emerging data is refocusing attention on potential therapies. With our small molecule clinical stage pipeline, AbFero is developing iron chelators for multiple indications. Jeff's depth of experience is mission critical to AbFero at this juncture."

SP-420, AbFero's lead chelator, has completed three Phase 1 clinical safety trials. The company's initial focus is in transfusion related iron overload (TIO). With SP-420's ability to cross the blood-brain and blood-retinal barriers, AbFero has expanded its pipeline to include therapeutic approaches to local iron overload implicated in neurodegenerative and retinal diseases.

"I'm delighted to join AbFero's committed leadership team, in particular because the company's technology is based upon discoveries by University of Florida Professor Ray Bergeron, whom I've worked with before," Jeff Harder said. "Bergeron technology coupled with AbFero's strategic expansion of its pipeline from transfusion related iron-overload to neurodegenerative and retinal indications made this a compelling opportunity. My corporate development experience will help AbFero achieve its mission of developing novel therapies for iron overload conditions."

Mr. Harder brings extensive experience in corporate development and governance to AbFero's management team. He was VP for Corporate Development and General Counsel at The ForeFront Group, Inc., a Nasdaq listed public company that he took public. Under his leadership, Forefront subsequently sold to CBG Group PLLC for nearly \$160 million. He also served on the board of several public and private companies, including Repros Therapeutics, Inc., and Sun BioPharma, Inc. Mr. Harder

obtained his undergrad degree at Valparaiso University with highest distinction and his juris doctor at the University of Illinois.

About AbFero

AbFero Pharmaceuticals, Inc. is a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload. Our therapeutic platform addresses transfusional iron overload (TIO) and iron accumulation associated with retinal and neurologic diseases including age-related macular degeneration (AMD), Parkinson's disease, and traumatic brain injury (TBI). AbFero has completed three clinical trials with the company's lead iron chelator, SP-420. AbFero Pharmaceuticals, Inc., is based in Boston, Massachusetts, and our subsidiary, AbFero, Ltd., is located in Harwell, UK.

Investor & Media Contact:

Mih-Ho Cha

mcha@abfero.com